Immunome, Inc. (IMNM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.76-1.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMNM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 6.7% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IMNM — earnings miss
Dated 2026-03-03
of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Why it matters: Funding is important for operations and growth. Clear funding news can change investor trust.
Watch forManagement shares news about a new funding round. This will help their operations.
Also watch forManagement says there are funding problems or delays in getting money.
Why it matters: If the healthcare sector's growth speeds up, it could benefit Immunome's performance. This is key for investor confidence.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: This data is crucial for understanding the product's potential. It could impact future funding and operations.
Supportive ifTopline data shows positive efficacy results in the Phase 3 trial.
Worry ifTopline data shows poor results or delays in reporting.
Why it matters: Updates on cash will explain funding for current operations and trials.
Watch forCash and cash equivalents are over $500 million. This funds operations until 2028.
Also watch forCash reserves are below $500 million. This raises concerns about funding.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$165 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $562 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,359 loss on $10,000 · 33.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The data will show how well varegacestat works for desmoid tumors. Positive results could boost investor confidence.
Supportive ifThe ASCO presentation got good feedback on the Phase 3 RINGSIDE trial results.
Worry ifThe ASCO presentation received bad feedback on the trial results.
Why it matters: Initial data will show the potential of IM-1021 in treating lymphoma. Positive results could enhance the pipeline's value.
Supportive ifInitial data for IM-1021 shows good responses in lymphoma patients.
Worry ifInitial data shows no good responses for IM-1021.